PULMONARY FIBROSIS AWARENESS MONTH
September is Pulmonary Fibrosis Awareness Month. Pulmonary Fibrosis (PF) is a family of more than 200 different lung diseases that all look very much alike. The word “pulmonary” means lung and “fibrosis” means scar tissue – so in its simplest sense, pulmonary fibrosis means scarring in the lungs. Interstitial Lung Disease (ILD) is a broad category of over 200 lung diseases that affect the lung interstitium. Typically, ILDs cause inflammation, fibrosis (scarring), or an accumulation of cells in the lung not due to infection or cancer. The prevalence of PF and ILD is on the rise with more than 50,000 new cases diagnosed annually; more than 250,000 Americans are living with PF and ILD.
The Pulmonary Fibrosis Foundation (PFF) is leading the charge to find a cure for pulmonary fibrosis, and the first step is to increase our knowledge of PF. For more information and resources about pulmonary fibrosis, visit their website!
Annual PF Walk
This year, we are proud to lead the way toward a world without pulmonary fibrosis (PF) as part of the PFF Walk. We hope you will join us as we raise funds to benefit the Pulmonary Fibrosis Foundation (PFF) in preparation for National Walk Day.
Join Our Team: https://secure.qgiv.com/event/20pwal/team/885988/register/
Make a Donation: https://secure.qgiv.com/event/20pwal/team/885988/
Pulmonary fibrosis is a deadly and complex disease that causes progressive scarring in the lungs. PF affects over 200,000 Americans annually and 50,000 people will be diagnosed this year alone.
While there is still significant work to be done, progress in the fight against pulmonary fibrosis is being made. Your generosity allows the PFF to expand essential efforts for the PF community.
For more information on how your gift will make a difference in the lives of PF patients and their families, please visit www.pulmonaryfibrosis.org.
Thank you in advance for your generous support.
National ILD Day
September 15th is National ILD Day. ILD, meaning Interstitial Lung Disease, is the umbrella term used for a large group of diseases characterized by inflammation and/or scarring in the lungs. This year, our nurses were hosted by Shefali Kimel from Boehringer Ingelheim Pharmaceuticals for a very informative presentation on Interstitial Lung Disease. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Thank you to Shefali and the guest speakers for a wonderful evening!
“Awareness of interstitial lung disease remains relatively unknown in the community, and because its symptoms are similar to other common respiratory diseases, it can be very difficult to diagnose,” said William T. Schmidt, president and CEO of the Pulmonary Fibrosis Foundation. “We created ILD Day, in partnership with eight other organizations, to raise awareness so at-risk patients and those experiencing symptoms can be diagnosed more quickly to receive proper care and treatment to manage the condition.”